TW586934B
(en)
*
|
1997-05-19 |
2004-05-11 |
Sumitomo Pharma |
Immunopotentiating composition
|
US7241730B2
(en)
|
1998-08-27 |
2007-07-10 |
Universitat Zurich |
Enzyme-mediated modification of fibrin for tissue engineering: fibrin formulations with peptides
|
US20020081732A1
(en)
*
|
2000-10-18 |
2002-06-27 |
Bowlin Gary L. |
Electroprocessing in drug delivery and cell encapsulation
|
US7615373B2
(en)
*
|
1999-02-25 |
2009-11-10 |
Virginia Commonwealth University Intellectual Property Foundation |
Electroprocessed collagen and tissue engineering
|
US20040018226A1
(en)
*
|
1999-02-25 |
2004-01-29 |
Wnek Gary E. |
Electroprocessing of materials useful in drug delivery and cell encapsulation
|
US6083933A
(en)
*
|
1999-04-19 |
2000-07-04 |
Stellar International Inc. |
Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
|
AU3438199A
(en)
*
|
1999-04-22 |
2000-11-10 |
Eth Zurich |
Controlled release of growth factors from heparin containing matrices
|
WO2001066164A1
(en)
*
|
1999-04-22 |
2001-09-13 |
Eidgenossisch Technische Hochschule Zurich |
Modified protein matrices
|
EP1315756A2
(de)
*
|
2000-09-01 |
2003-06-04 |
Virginia Commonwealth University Intellectual Property Foundation |
Elektroplattierte fibrin-basierte träger und gewebe
|
CA2325842C
(en)
*
|
2000-11-02 |
2007-08-07 |
Lisa Mckerracher |
Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof
|
US7182944B2
(en)
*
|
2001-04-25 |
2007-02-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Methods of increasing distribution of nucleic acids
|
US7906102B2
(en)
|
2001-10-03 |
2011-03-15 |
Vanderbilt University |
Ligands to radiation-induced molecules
|
WO2003041723A1
(de)
*
|
2001-11-12 |
2003-05-22 |
Reinmueller Johannes |
Pharmazeutische anwendungen von hyaluronsäure-präparaten
|
WO2003066083A1
(fr)
*
|
2002-02-04 |
2003-08-14 |
Sumitomo Pharmaceuticals Company, Limited |
Preparations pour le traitement de fracture osseuse de deperdition osseuse ou d'augmentation la densite osseuse
|
US20030216315A1
(en)
|
2002-02-13 |
2003-11-20 |
Duke University |
Modulation of immune response by non-peptide binding stress response polypeptides
|
US20080159957A1
(en)
|
2002-10-01 |
2008-07-03 |
W Michael Kavanaugh |
Anti-Cancer and Anti-Infectious Disease Compositions and Methods for Using Same
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
US20040161476A1
(en)
|
2003-02-19 |
2004-08-19 |
Hahn Sungtack Samuel |
Cystitis treatment with high dose chondroitin sulfate
|
EP1682537B1
(de)
|
2003-11-05 |
2012-03-28 |
SARcode Bioscience Inc. |
Modulatoren der zellulären adhäsion
|
FR2862878B1
(fr)
*
|
2003-11-27 |
2006-03-24 |
Sofradim Production |
Substrat metallique revetu d'une composition de collagene et de polysaccharides, procede et applications
|
GB0402131D0
(en)
|
2004-01-30 |
2004-03-03 |
Isis Innovation |
Delivery method
|
US20060039949A1
(en)
*
|
2004-08-20 |
2006-02-23 |
Nycz Jeffrey H |
Acetabular cup with controlled release of an osteoinductive formulation
|
US20060045902A1
(en)
*
|
2004-09-01 |
2006-03-02 |
Serbousek Jon C |
Polymeric wrap for in vivo delivery of osteoinductive formulations
|
US20060057184A1
(en)
*
|
2004-09-16 |
2006-03-16 |
Nycz Jeffrey H |
Process to treat avascular necrosis (AVN) with osteoinductive materials
|
US8137664B2
(en)
*
|
2005-02-02 |
2012-03-20 |
Sdgi Holdings, Inc. |
Method and kit for repairing a defect in bone
|
US20090156545A1
(en)
*
|
2005-04-01 |
2009-06-18 |
Hostetler Karl Y |
Substituted Phosphate Esters of Nucleoside Phosphonates
|
WO2006137953A1
(en)
|
2005-04-01 |
2006-12-28 |
The Regents Of The Univerisity Of California |
Phosphono-pent-2-en-1-yl nucleosides and analogs
|
EP2444079B1
(de)
|
2005-05-17 |
2016-11-30 |
SARcode Bioscience Inc. |
Zusammensetzungen und Verfahren zur Behandlung von Augenerkrankungen
|
ES2664086T3
(es)
|
2005-12-30 |
2018-04-18 |
Zensun (Shanghai) Science & Technology, Co., Ltd. |
Liberación extendida de neurregulina para mejorar la función cardíaca
|
EP1993590B1
(de)
*
|
2006-03-01 |
2013-12-25 |
Biogen Idec MA Inc. |
Zusammensetzungen und verfahren zur verabreichung von proteinen der gdnf-liganden-familie
|
WO2007106494A2
(en)
*
|
2006-03-13 |
2007-09-20 |
Encysive Pharmaceuticals, Inc. |
Methods and compositions for treatment of diastolic heart failure
|
EP2383271B1
(de)
|
2006-03-13 |
2013-07-10 |
Kyorin Pharmaceutical Co., Ltd. |
Aminochinolone als GSK-3-Hemmer
|
JP2009530280A
(ja)
*
|
2006-03-13 |
2009-08-27 |
エンサイシブ・ファーマシューティカルズ・インコーポレイテッド |
シタクスセンタンナトリウムの配合物
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
BRPI0716897A2
(pt)
|
2006-09-21 |
2013-10-22 |
Activx Biosciences Inc |
Composto ou um derivado farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir uma ação de uma serina hidrolase e para tratamento de uma doença mediada por serina hidrolase, e, artigo de fabricação.
|
CA2666149A1
(en)
|
2006-10-19 |
2008-04-24 |
Auspex Pharmaceuticals, Inc. |
Substituted indoles
|
WO2008057604A2
(en)
*
|
2006-11-08 |
2008-05-15 |
The Regents Of The University Of California |
Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
|
EP2125739A1
(de)
*
|
2006-12-22 |
2009-12-02 |
Encysive Pharmaceuticals, Inc. |
Modulatoren des c3a-rezeptors und verfahren zu deren anwendung
|
PL2144604T3
(pl)
*
|
2007-02-28 |
2012-02-29 |
Conatus Pharmaceuticals Inc |
Sposoby leczenia przewlekłego zapalenia wątroby typu C z zastosowaniem RO 113-0830
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
ES2605371T3
(es)
|
2007-03-15 |
2017-03-14 |
Auspex Pharmaceuticals, Inc. |
D9-Venlafaxina deuterada
|
US7892776B2
(en)
|
2007-05-04 |
2011-02-22 |
The Regents Of The University Of California |
Screening assay to identify modulators of protein kinase A
|
EP2998314B1
(de)
|
2007-06-04 |
2020-01-22 |
Bausch Health Ireland Limited |
Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
EA201000016A1
(ru)
*
|
2007-07-12 |
2010-10-29 |
Трагара Фармасьютикалс, Инк. |
Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
|
ATE531721T1
(de)
*
|
2007-09-11 |
2011-11-15 |
Kyorin Seiyaku Kk |
Cyanoaminochinolone als gsk-3-inhibitoren
|
US8476261B2
(en)
|
2007-09-12 |
2013-07-02 |
Kyorin Pharmaceutical Co., Ltd. |
Spirocyclic aminoquinolones as GSK-3 inhibitors
|
CN101873797A
(zh)
*
|
2007-10-19 |
2010-10-27 |
萨可德公司 |
用于治疗糖尿病性视网膜病的组合物和方法
|
CA2745339C
(en)
|
2007-12-24 |
2016-06-28 |
The University Of Queensland |
Coating method
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
WO2009097660A1
(en)
|
2008-02-07 |
2009-08-13 |
The University Of Queensland |
Patch production
|
HUE032873T2
(en)
|
2008-03-17 |
2017-11-28 |
Ambit Biosciences Corp |
1- (3- (6,7-Dimethoxyquinazolin-4-yloxy) phenyl) -3- (5- (1,1,1-trifluoro-2-methylpropan-2-yl) isoxazol-3-yl) urea as RAF kinase inhibitor for the treatment of cancer
|
US20090258069A1
(en)
*
|
2008-04-15 |
2009-10-15 |
John Burnier |
Delivery of LFA-1 antagonists to the gastrointestinal system
|
US8080562B2
(en)
*
|
2008-04-15 |
2011-12-20 |
Sarcode Bioscience Inc. |
Crystalline pharmaceutical and methods of preparation and use thereof
|
US20090298882A1
(en)
*
|
2008-05-13 |
2009-12-03 |
Muller George W |
Thioxoisoindoline compounds and compositions comprising and methods of using the same
|
MX2010012514A
(es)
*
|
2008-05-20 |
2011-05-30 |
Cerenis Therapeutics S A |
Niacina y un medicamento nsaid para tratamiento combinado.
|
WO2009140735A1
(en)
*
|
2008-05-23 |
2009-11-26 |
The University Of Queensland |
Analyte detection by microneedle patch with analyte selective reagents.
|
WO2009149279A2
(en)
|
2008-06-04 |
2009-12-10 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
EP2307434B1
(de)
|
2008-07-02 |
2014-02-12 |
IDENIX Pharmaceuticals, Inc. |
Verbindungen und pharmazeutische zusammensetzungen für die behandlung von virusinfektionen
|
WO2010009319A2
(en)
|
2008-07-16 |
2010-01-21 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
WO2010042815A2
(en)
*
|
2008-10-09 |
2010-04-15 |
Duke University |
Vhh antibody fragments for use in the detection and treatment of cancer
|
CA2760573A1
(en)
|
2008-12-22 |
2010-07-01 |
The University Of Queensland |
Patch production
|
CN102307892A
(zh)
|
2008-12-31 |
2012-01-04 |
西尼克斯公司 |
环孢菌素a的衍生物
|
WO2010088450A2
(en)
|
2009-01-30 |
2010-08-05 |
Celladon Corporation |
Methods for treating diseases associated with the modulation of serca
|
US8568793B2
(en)
|
2009-02-11 |
2013-10-29 |
Hope Medical Enterprises, Inc. |
Sodium nitrite-containing pharmaceutical compositions
|
JP5746981B2
(ja)
|
2009-02-27 |
2015-07-08 |
アムビト ビオスシエンセス コルポラチオン |
Jakキナーゼ調節キナゾリン誘導体、及びその使用方法
|
US8193372B2
(en)
|
2009-03-04 |
2012-06-05 |
Idenix Pharmaceuticals, Inc. |
Phosphothiophene and phosphothiazole HCV polymerase inhibitors
|
JP2012520314A
(ja)
|
2009-03-11 |
2012-09-06 |
アムビト ビオスシエンセス コルポラチオン |
癌治療のためのインダゾリルアミノピロロトリアジンとタキサンの併用
|
CN102421784B
(zh)
*
|
2009-03-11 |
2015-09-30 |
杏林制药株式会社 |
作为gsk-3抑制剂的7-环烷基氨基喹诺酮
|
KR20110136880A
(ko)
|
2009-03-27 |
2011-12-21 |
패스웨이 테라퓨틱스 인코포레이티드 |
피리미딘일 및 1,3,5-트라이아진일 벤즈이미다졸 설폰아미드 및 암 치료법에서의 이의 용도
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
MX2011011139A
(es)
|
2009-04-22 |
2012-01-27 |
Axikin Pharmaceuticals Inc |
Antagonistas ccr3 arisulfonamida 2, 5-disustituidos.
|
KR20120034627A
(ko)
|
2009-04-22 |
2012-04-12 |
액시킨 파마수티컬스 인코포레이티드 |
아릴설폰아마이드 ccr3 길항제
|
MY162440A
(en)
|
2009-04-22 |
2017-06-15 |
Axikin Pharmaceuticals Inc |
2,5-disubstituted arylsulfonamide ccr3 antagonists
|
WO2011003870A2
(en)
|
2009-07-06 |
2011-01-13 |
Creabilis S.A. |
Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
|
CA2767008C
(en)
|
2009-07-07 |
2018-01-30 |
Pathway Therapeutics, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
PT2451435T
(pt)
|
2009-07-08 |
2018-01-15 |
Hope Medical Entpr Inc D B A Hope Pharmaceuticals |
Composições farmacêuticas que contêm tiossulfato de sódio
|
WO2011009961A1
(en)
|
2009-07-24 |
2011-01-27 |
Virologik Gmbh |
Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
|
AR077712A1
(es)
|
2009-08-05 |
2011-09-14 |
Idenix Pharmaceuticals Inc |
Inhibidores de serina proteasa macrociclica
|
KR20120059558A
(ko)
|
2009-08-19 |
2012-06-08 |
암비트 바이오사이언시즈 코포레이션 |
바이아릴 화합물 및 이의 사용 방법
|
US8518405B2
(en)
|
2009-10-08 |
2013-08-27 |
The University Of North Carolina At Charlotte |
Tumor specific antibodies and uses therefor
|
US8378105B2
(en)
|
2009-10-21 |
2013-02-19 |
Sarcode Bioscience Inc. |
Crystalline pharmaceutical and methods of preparation and use thereof
|
WO2011056566A2
(en)
|
2009-10-26 |
2011-05-12 |
Sunesis Pharmaceuticals, Inc. |
Compounds and methods for treatment of cancer
|
WO2011056764A1
(en)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
|
WO2011064769A1
(en)
|
2009-11-24 |
2011-06-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Methods and pharmaceutical compositions for the treatment of hot flashes
|
WO2011069002A1
(en)
|
2009-12-02 |
2011-06-09 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
CN102822175A
(zh)
|
2009-12-18 |
2012-12-12 |
埃迪尼克斯医药公司 |
5,5-稠合的亚芳基或亚杂芳基丙型肝炎病毒抑制剂
|
SG181896A1
(en)
*
|
2009-12-23 |
2012-07-30 |
Map Pharmaceuticals Inc |
Novel ergoline analogs
|
AU2010339460A1
(en)
|
2009-12-30 |
2012-07-19 |
Scynexis Inc. |
Cyclosporine analogues
|
WO2011089166A1
(en)
|
2010-01-19 |
2011-07-28 |
Virologik Gmbh |
Semicarbazone proteasome inhibitors for treating hiv and hepatitis infection
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
WO2011097525A1
(en)
|
2010-02-05 |
2011-08-11 |
Tragara Pharmaceuticals, Inc. |
Solid state forms of macrocyclic kinase inhibitors
|
MX337169B
(es)
|
2010-02-11 |
2016-02-16 |
Celgene Corp |
Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos.
|
CA2791964A1
(en)
|
2010-03-02 |
2011-09-09 |
Axikin Pharmaceuticals, Inc. |
Isotopically enriched arylsulfonamide ccr3 antagonists
|
WO2011112689A2
(en)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Saltz of an indazolylpyrrolotriazine
|
EP2547655B1
(de)
|
2010-03-17 |
2016-03-09 |
Axikin Pharmaceuticals, Inc. |
Arylsulfonamid-ccr-3-antagonisten
|
WO2011150201A2
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl amide compounds and methods of use thereof
|
WO2011150198A1
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl urea compounds and methods of use thereof
|
CN103153309A
(zh)
|
2010-06-01 |
2013-06-12 |
拜欧赛里克斯公司 |
使用6-环己基-1-羟基-4-甲基-2(1h)-吡啶酮治疗血液恶性肿瘤的方法
|
CN104945318A
(zh)
|
2010-06-01 |
2015-09-30 |
拜欧赛里克斯公司 |
羟基吡啶酮衍生物、其药物组合物及其用于治疗增生性疾病的治疗用途
|
CN104860907A
(zh)
|
2010-06-07 |
2015-08-26 |
诺沃梅迪科斯有限公司 |
呋喃基化合物及其用途
|
WO2012006677A1
(en)
|
2010-07-14 |
2012-01-19 |
The University Of Queensland |
Patch applying apparatus
|
US20130178522A1
(en)
|
2010-07-19 |
2013-07-11 |
James M. Jamison |
Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
|
WO2012030924A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Azolopyridine and azolopyrimidine compounds and methods of use thereof
|
EP2611795B1
(de)
|
2010-09-01 |
2016-05-04 |
Ambit Biosciences Corporation |
Optisch aktives pyrazolylaminochinazolin sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür
|
EP2611789A1
(de)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Chinazolinverbindungen und anwendungsverfahren dafür
|
EP2611793A1
(de)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
2-cyclochinazolinderivate und verwendungsverfahren dafür
|
WO2012030894A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Thienopyridine and thienopyrimidine compounds and methods of use thereof
|
US20120053176A1
(en)
|
2010-09-01 |
2012-03-01 |
Ambit Biosciences Corp. |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
US20130225578A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
7-cyclylquinazoline derivatives and methods of use thereof
|
US20130225614A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
CA2809983A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Hydrobromide salts of a pyrazolylaminoquinazoline
|
EP2663553B1
(de)
|
2010-09-01 |
2015-08-26 |
Ambit Biosciences Corporation |
Chinolin- und isochinolinverbindungen zur verwendung als jak-modulatoren
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
WO2012044641A1
(en)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
MX2013003954A
(es)
|
2010-10-11 |
2013-08-01 |
Axikin Pharmaceuticals Inc |
Sales de arilsulfonamida antagonistas de ccr3.
|
CA2817577A1
(en)
|
2010-11-10 |
2012-05-18 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US20140079686A1
(en)
|
2010-12-06 |
2014-03-20 |
Shikha P. Barman |
Methods For Treating Baldness And Promoting Hair Growth
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
MY166537A
(en)
|
2010-12-14 |
2018-07-10 |
Nat Univ Singapore |
Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
|
DK2663309T3
(en)
|
2011-01-10 |
2017-06-19 |
Infinity Pharmaceuticals Inc |
METHODS FOR PRODUCING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES
|
CA2825152A1
(en)
|
2011-01-31 |
2012-08-09 |
Celgene Corporation |
Pharmaceutical compositions of cytidine analogs and methods of use thereof
|
TW201309690A
(zh)
|
2011-02-10 |
2013-03-01 |
Idenix Pharmaceuticals Inc |
巨環絲胺酸蛋白酶抑制劑,其醫藥組合物及其於治療hcv感染之用途
|
RU2013145556A
(ru)
|
2011-03-11 |
2015-04-20 |
Селджин Корпорейшн |
Применение 3-(5-амино-2-метил-4-оксохиназолин-3(4н)-ил)пиперидин-2,6-диона в лечении иммунных и воспалительных заболеваний
|
TWI572599B
(zh)
|
2011-03-28 |
2017-03-01 |
Mei製藥公司 |
(α-經取代之芳烷胺基及雜芳烷胺基)嘧啶基及1,3,5-三基苯并咪唑,其醫藥組合物及其在治療增生性疾病之用途
|
AU2012236722A1
(en)
|
2011-03-28 |
2013-10-17 |
Mei Pharma, Inc. |
(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
EP2691388A1
(de)
|
2011-03-28 |
2014-02-05 |
MEI Pharma, Inc. |
(kondensierte arylamino- und heterocyclylamino-)pyrimidynyl und 1,3,5-triazinyl-benzimidazole, pharmazeutische zusammensetzungen daraus und ihre verwendung zur behandlung von proliferativen erkrankungen
|
WO2012154321A1
(en)
|
2011-03-31 |
2012-11-15 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
US9453020B2
(en)
|
2011-05-04 |
2016-09-27 |
Balance Therapeutics, Inc. |
Substituted pentylenetetrazoles as GABA receptor activity modulators
|
JP2014517076A
(ja)
|
2011-06-23 |
2014-07-17 |
マップ・ファーマシューティカルズ・インコーポレイテッド |
新規のフルオロエルゴリン類似体
|
AU2012284088B2
(en)
|
2011-07-19 |
2015-10-08 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
MX2014000648A
(es)
|
2011-07-19 |
2014-09-25 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y sus usos.
|
KR20140075693A
(ko)
|
2011-08-29 |
2014-06-19 |
인피니티 파마슈티칼스, 인코포레이티드 |
헤테로사이클릭 화합물 및 그의 용도
|
AR088441A1
(es)
|
2011-09-12 |
2014-06-11 |
Idenix Pharmaceuticals Inc |
Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
|
JP2014526474A
(ja)
|
2011-09-12 |
2014-10-06 |
アイディニックス ファーマシューティカルズ インコーポレイテッド |
ウイルス感染の治療のための化合物および薬学的組成物
|
US9630979B2
(en)
|
2011-09-29 |
2017-04-25 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
WO2013053022A1
(en)
|
2011-10-12 |
2013-04-18 |
The University Of Queensland |
Delivery device
|
US8507460B2
(en)
|
2011-10-14 |
2013-08-13 |
Idenix Pharmaceuticals, Inc. |
Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
KR102066297B1
(ko)
|
2011-10-14 |
2020-01-14 |
암비트 바이오사이언시즈 코포레이션 |
헤테로사이클릭 화합물 및 이의 유형 3 수용체 티로신 키나아제의 조절인자로서의 용도
|
CA2859173A1
(en)
|
2011-12-19 |
2013-06-27 |
Map Pharmaceuticals, Inc. |
Novel iso-ergoline derivatives
|
SG10201506202RA
(en)
|
2011-12-21 |
2015-09-29 |
Map Pharmaceuticals Inc |
Novel neuromodulatory compounds
|
WO2013130600A1
(en)
|
2012-02-29 |
2013-09-06 |
Ambit Biosciences Corporation |
Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
|
WO2013138617A1
(en)
|
2012-03-16 |
2013-09-19 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2013177195A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphate prodrugs for hcv infection
|
WO2013177219A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
D-amino acid compounds for liver disease
|
US9109001B2
(en)
|
2012-05-22 |
2015-08-18 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphoramidate prodrugs for HCV infection
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
CN104797574B
(zh)
|
2012-07-25 |
2019-11-22 |
原生质生物科学股份有限公司 |
Lfa-1抑制剂及其多晶型物
|
CN114939119A
(zh)
|
2012-08-09 |
2022-08-26 |
细胞基因公司 |
免疫相关和炎性疾病的治疗
|
KR20150041123A
(ko)
|
2012-08-09 |
2015-04-15 |
셀진 코포레이션 |
(s)-3-(4-((4-(몰폴리노메틸)벤질)옥시)-1-옥소아이소인돌린-2-일)피페리딘-2,6-다이온의 염 및 고체 형태 및 이를 포함하는 조성물 및 이를 사용하는 방법
|
CA2922849A1
(en)
|
2012-08-31 |
2014-03-06 |
Ixchel Pharma, Llc |
Agents useful for treating obesity, diabetes and related disorders
|
EP2892884A1
(de)
|
2012-09-07 |
2015-07-15 |
Axikin Pharmaceuticals, Inc. |
Isotopisch angereicherte arylsulfonamid-ccr3-antagonisten
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
US10513534B2
(en)
|
2012-10-08 |
2019-12-24 |
Idenix Pharmaceuticals Llc |
2′-chloro nucleoside analogs for HCV infection
|
EP2909223B1
(de)
|
2012-10-19 |
2017-03-22 |
Idenix Pharmaceuticals LLC |
Dinukleotidverbindungen für hcv-infektion
|
WO2014066239A1
(en)
|
2012-10-22 |
2014-05-01 |
Idenix Pharmaceuticals, Inc. |
2',4'-bridged nucleosides for hcv infection
|
DK2914296T4
(da)
|
2012-11-01 |
2022-01-03 |
Infinity Pharmaceuticals Inc |
Behandling af cancere under anvendelse af PI3-kinase-isoform-modulatorer
|
US20150272924A1
(en)
|
2012-11-08 |
2015-10-01 |
Summa Health System |
Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
|
US20140140951A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Rp-Nucleoside Analog
|
WO2014078436A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of sp-nucleoside analog
|
US9156781B2
(en)
|
2012-11-30 |
2015-10-13 |
Novomedix, Llc |
Substituted biaryl sulfonamides and the use thereof
|
EP2935304A1
(de)
|
2012-12-19 |
2015-10-28 |
IDENIX Pharmaceuticals, Inc. |
4'-fluor-nukleoside zur behandlung von hcv
|
SG11201504931SA
(en)
|
2012-12-21 |
2015-07-30 |
Map Pharmaceuticals Inc |
Novel methysergide derivatives
|
WO2014110305A1
(en)
|
2013-01-11 |
2014-07-17 |
Mayo Foundation For Medical Education And Research |
Vitamins c and k for treating polycystic diseases
|
EP3718557A3
(de)
|
2013-02-25 |
2020-10-21 |
Bausch Health Ireland Limited |
Guanylat-cyclase-rezeptoragonist sp-333 zur verwendung in der darmreinigung
|
US9309275B2
(en)
|
2013-03-04 |
2016-04-12 |
Idenix Pharmaceuticals Llc |
3′-deoxy nucleosides for the treatment of HCV
|
WO2014137930A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
Thiophosphate nucleosides for the treatment of hcv
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
EP2970194A1
(de)
|
2013-03-15 |
2016-01-20 |
Infinity Pharmaceuticals, Inc. |
Salze und feste formen von isochinolinonen und zusammensetzung damit sowie verfahren zur verwendung davon
|
US9187515B2
(en)
|
2013-04-01 |
2015-11-17 |
Idenix Pharmaceuticals Llc |
2′,4′-fluoro nucleosides for the treatment of HCV
|
DK3003309T3
(da)
|
2013-05-30 |
2020-12-14 |
Infinity Pharmaceuticals Inc |
Behandling af cancer med PI3-kinase-isoform modulatorer
|
EP3004130B1
(de)
|
2013-06-05 |
2019-08-07 |
Idenix Pharmaceuticals LLC. |
1',4'-thionukleoside zur behandlung von hcv
|
EP3027636B1
(de)
|
2013-08-01 |
2022-01-05 |
Idenix Pharmaceuticals LLC |
D-amino acid phosphoramidate pronucleotide of halogenierte pyrimidine verbindungen für leber krankheiten
|
RU2016111675A
(ru)
|
2013-08-30 |
2017-10-04 |
Эмбит Байосайенсиз Корпорейшн |
Соединения биарилацетамида и способы их применения
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
WO2015042375A1
(en)
|
2013-09-20 |
2015-03-26 |
Idenix Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
WO2015051336A1
(en)
|
2013-10-03 |
2015-04-09 |
David Wise |
Compositions and methods for treating pelvic pain and other conditions
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
NZ718430A
(en)
|
2013-10-04 |
2021-12-24 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and uses thereof
|
EA201690732A1
(ru)
|
2013-10-10 |
2016-12-30 |
Синерджи Фармасьютикалз, Инк. |
Агонисты гуанилатциклазы, используемые для лечения индуцированных опиоидами дисфункций
|
US20160244452A1
(en)
|
2013-10-21 |
2016-08-25 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
EP3063165A1
(de)
|
2013-11-01 |
2016-09-07 |
Idenix Pharmaceuticals LLC |
D-alanin-phosphoramidat-pronukleotide von 2'-methyl-2'-fluor-guanosin-nukleosid-verbindungen zur behandlung von hcv
|
EP3074399A1
(de)
|
2013-11-27 |
2016-10-05 |
Idenix Pharmaceuticals LLC |
2'-dichlor- und 2'-fluor-2'-chlor-nukleosidanaloga für hcv-infektion
|
CA2931458A1
(en)
|
2013-11-27 |
2015-06-04 |
Idenix Pharmaceuticals Llc |
Nucleotides for the treatment of liver cancer
|
EP3083654A1
(de)
|
2013-12-18 |
2016-10-26 |
Idenix Pharmaceuticals LLC |
4'-or-nukleoside zur behandlung von hcv
|
US11135316B2
(en)
|
2014-01-31 |
2021-10-05 |
Washington University |
Imaging and treatment of pathophysiologic conditions by Cerenkov radiation
|
EP3114122A1
(de)
|
2014-03-05 |
2017-01-11 |
Idenix Pharmaceuticals LLC |
Feste formen einer flaviviridae-virus-hemmerverbindung und salze davon
|
EA201691872A1
(ru)
|
2014-03-19 |
2017-04-28 |
Инфинити Фармасьютикалз, Инк. |
Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
|
CA2943231C
(en)
|
2014-03-20 |
2023-10-24 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
|
ES2891734T3
(es)
|
2014-03-20 |
2022-01-31 |
Capella Therapeutics Inc |
Derivados de bencimidazol como inhibidores de tirosina quinasa ERBB para el tratamiento del cáncer
|
WO2015157559A2
(en)
|
2014-04-09 |
2015-10-15 |
Siteone Therapeutics, Inc. |
10',11'-modified saxitoxins for the treatment of pain
|
US10202411B2
(en)
|
2014-04-16 |
2019-02-12 |
Idenix Pharmaceuticals Llc |
3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
CA2948540A1
(en)
|
2014-05-12 |
2015-11-19 |
Conatus Pharmaceuticals Inc. |
Treatment of the complications of chronic liver disease with caspase inhibitors
|
JP2017516779A
(ja)
|
2014-05-28 |
2017-06-22 |
アイデニクス・ファーマシューティカルズ・エルエルシー |
癌治療のためのヌクレオシド誘導体
|
US9974870B2
(en)
|
2014-06-09 |
2018-05-22 |
Washington University |
Compositions and methods for treatment and imaging using nanoparticles
|
US9527815B2
(en)
|
2014-06-18 |
2016-12-27 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
|
CN106559991B
(zh)
|
2014-06-19 |
2019-09-20 |
阿里亚德医药股份有限公司 |
用于激酶抑制的杂芳基化合物
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
EP3172238B1
(de)
|
2014-07-23 |
2020-09-23 |
Ohio State Innovation Foundation |
Verfahren und zusammensetzungen im zusammenhang mit antikörperfragmenten zur bindung an das tumorassoziierte glycoprotein 72 (tag 72)
|
EP3172222A4
(de)
|
2014-07-24 |
2018-03-21 |
Washington University |
Gegen strahlungsinduzierte moleküle gerichtete zusammensetzungen und verfahren zur verwendung davon
|
BR112017004708A2
(pt)
|
2014-09-12 |
2017-12-05 |
Tobira Therapeutics Inc |
terapia de combinação de cenicriviroc para o tratamento de fibrose
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
AU2015335950B2
(en)
|
2014-10-21 |
2018-01-25 |
Takeda Pharmaceutical Company Limited |
Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl) phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] phenyl}pyrimidine-2,4-diamine
|
EP3209658A1
(de)
|
2014-10-24 |
2017-08-30 |
Biogen MA Inc. |
Diterpenoidderivate und verfahren zur verwendung
|
WO2016106309A1
(en)
|
2014-12-23 |
2016-06-30 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
CA2974117A1
(en)
|
2015-01-20 |
2016-07-28 |
Xoc Pharmaceuticals, Inc. |
Ergoline compounds and uses thereof
|
MX2017009406A
(es)
|
2015-01-20 |
2018-01-18 |
Xoc Pharmaceuticals Inc |
Compuestos de tipo isoergolina y usos de estos.
|
US11147954B2
(en)
|
2015-02-02 |
2021-10-19 |
Vaxxas Pty Limited |
Microprojection array applicator and method
|
US10815264B2
(en)
|
2015-05-27 |
2020-10-27 |
Southern Research Institute |
Nucleotides for the treatment of cancer
|
EP3313402B1
(de)
|
2015-06-23 |
2023-12-27 |
Neurocrine Biosciences, Inc. |
Vmat2-inhibitoren zur behandlung von neurologischen krankheiten oder störungen
|
KR20210048600A
(ko)
|
2015-08-17 |
2021-05-03 |
쿠라 온콜로지, 인크. |
파르네실전달효소 억제제를 이용하여 암환자를 치료하는 방법
|
US11103259B2
(en)
|
2015-09-18 |
2021-08-31 |
Vaxxas Pty Limited |
Microprojection arrays with microprojections having large surface area profiles
|
CN108473503A
(zh)
|
2015-09-30 |
2018-08-31 |
赛特温治疗公司 |
用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
|
CN108473489B
(zh)
|
2015-10-30 |
2022-09-02 |
纽罗克里生物科学有限公司 |
Valbenazine盐及其多晶形物
|
WO2017079566A1
(en)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Caspase inhibitors for use in the treatment of liver cancer
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
LT3394057T
(lt)
|
2015-12-23 |
2022-06-27 |
Neurocrine Biosciences, Inc. |
Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą)
|
WO2017117478A1
(en)
|
2015-12-31 |
2017-07-06 |
Conatus Pharmaceuticals Inc. |
Methods of using caspase inhibitors in treatment of liver disease
|
US10648983B2
(en)
|
2016-01-08 |
2020-05-12 |
Celgene Corporation |
Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
|
AR107320A1
(es)
|
2016-01-08 |
2018-04-18 |
Celgene Corp |
Formas sólidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoindolin-5-il)metil)-2,2-difluoroacetamida y sus composiciones farmacéuticas y usos
|
SG10202003099XA
(en)
|
2016-01-08 |
2020-05-28 |
Celgene Corp |
Antiproliferative compounds, and their pharmaceutical compositions and uses
|
CN108884130B
(zh)
|
2016-01-11 |
2022-09-13 |
博士医疗爱尔兰有限公司 |
用于治疗溃疡性结肠炎的制剂和方法
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
CN108884019A
(zh)
|
2016-04-11 |
2018-11-23 |
克雷西奥生物科技有限公司 |
氘代氯胺酮衍生物
|
WO2017180794A1
(en)
|
2016-04-13 |
2017-10-19 |
Skyline Antiinfectives, Inc. |
Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
|
WO2017184968A1
(en)
|
2016-04-22 |
2017-10-26 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
KR102498741B1
(ko)
|
2016-04-29 |
2023-02-10 |
에프지에이치 바이오테크 인코포레이티드 |
질환 치료용 이-치환된 피라졸 화합물
|
TWI753910B
(zh)
|
2016-05-16 |
2022-02-01 |
美商拜歐斯瑞克斯公司 |
吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US11339142B2
(en)
|
2016-09-07 |
2022-05-24 |
Fgh Biotech, Inc. |
Di-substituted pyrazole compounds for the treatment of diseases
|
CN109982687A
(zh)
|
2016-09-19 |
2019-07-05 |
梅制药公司 |
联合疗法
|
AU2017353838A1
(en)
|
2016-11-03 |
2019-05-23 |
Kura Oncology, Inc. |
Farnesyltransferase inhibitors for use in methods of treating cancer
|
US10988442B2
(en)
|
2016-11-09 |
2021-04-27 |
Novomedix, Llc |
Nitrite salts of 1,1-dimethylbiguanide, pharmaceutical compositions, and methods of use
|
US10106521B2
(en)
|
2016-11-09 |
2018-10-23 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
EP3548007A4
(de)
|
2016-12-01 |
2020-08-12 |
Ignyta, Inc. |
Verfahren zur behandlung von krebs
|
JP2020500875A
(ja)
|
2016-12-02 |
2020-01-16 |
ニューロクライン バイオサイエンシーズ,インコーポレイテッド |
統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
|
SG11201906883SA
(en)
|
2017-01-27 |
2019-08-27 |
Neurocrine Biosciences Inc |
Methods for the administration of certain vmat2 inhibitors
|
US9956215B1
(en)
|
2017-02-21 |
2018-05-01 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
MX2019009821A
(es)
|
2017-02-21 |
2019-12-02 |
Kura Oncology Inc |
Metodos para tratar cancer con inhibidores de farnesiltransferasa.
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
US11555031B2
(en)
|
2017-03-20 |
2023-01-17 |
The Broad Institute, Inc. |
Compounds and methods for regulating insulin secretion
|
US11236097B2
(en)
|
2017-03-29 |
2022-02-01 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
EP3601290B1
(de)
|
2017-03-29 |
2021-11-24 |
Siteone Therapeutics, Inc. |
11,13-modifizierte saxitoxine zur behandlung von schmerzen
|
ES2960937T3
(es)
|
2017-03-31 |
2024-03-07 |
Vaxxas Pty Ltd |
Dispositivo y método para recubrir superficies
|
US20200179352A1
(en)
|
2017-04-26 |
2020-06-11 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
JOP20190219A1
(ar)
|
2017-05-09 |
2019-09-22 |
Cardix Therapeutics LLC |
تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
MA49141A
(fr)
|
2017-05-19 |
2020-03-25 |
Nflection Therapeutics Inc |
Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau
|
CA3063535A1
(en)
|
2017-05-19 |
2018-11-22 |
Nflection Therapeutics, Inc. |
Fused heteroaromatic-aniline compounds for treatment of dermal disorders
|
EP3630758A1
(de)
|
2017-06-01 |
2020-04-08 |
Xoc Pharmaceuticals, Inc |
Ergolinderivate zur verwendung in der medizin
|
US11175128B2
(en)
|
2017-06-13 |
2021-11-16 |
Vaxxas Pty Limited |
Quality control of substrate coatings
|
US11464957B2
(en)
|
2017-08-04 |
2022-10-11 |
Vaxxas Pty Limited |
Compact high mechanical energy storage and low trigger force actuator for the delivery of microprojection array patches (MAP)
|
TW201919628A
(zh)
|
2017-08-07 |
2019-06-01 |
美商庫拉腫瘤技術股份有限公司 |
以法尼基轉移酶(farnesyltransferase)抑制劑治療癌症之方法
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
AU2018335259A1
(en)
|
2017-09-21 |
2020-04-09 |
Neurocrine Biosciences, Inc. |
High dosage valbenazine formulation and compositions, methods, and kits related thereto
|
US10993941B2
(en)
|
2017-10-10 |
2021-05-04 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
CA3077149A1
(en)
|
2017-10-10 |
2019-04-18 |
Neurocrine Biosciences, Inc. |
Methods for the administration of (s)-2-amino-3-methyl-butyric acid (2r,3r,11br)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2yl ester and salts thereof
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
WO2019139871A1
(en)
|
2018-01-10 |
2019-07-18 |
Cura Therapeutics Llc |
Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
|
JP7395480B2
(ja)
|
2018-01-10 |
2023-12-11 |
クラ セラピューティクス, エルエルシー |
フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用
|
SG11202011544UA
(en)
|
2018-06-14 |
2020-12-30 |
Neurocrine Biosciences Inc |
Vmat2 inhibitor compounds, compositions, and methods relating thereto
|
WO2020006341A1
(en)
|
2018-06-29 |
2020-01-02 |
Conatus Pharmaceuticals, Inc. |
(s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
|
KR20210044817A
(ko)
|
2018-08-15 |
2021-04-23 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
US20220009938A1
(en)
|
2018-10-03 |
2022-01-13 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
US20220002396A1
(en)
|
2018-11-01 |
2022-01-06 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2020106307A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks
|
US11572344B2
(en)
|
2018-11-20 |
2023-02-07 |
Nflection Therapeutics, Inc. |
Cyanoaryl-aniline compounds for treatment of dermal disorders
|
CA3120337A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Naphthyridinone-aniline compounds for treatment of dermal disorders
|
MA55143A
(fr)
|
2018-11-20 |
2021-09-29 |
H Lee Moffitt Cancer Center & Res Institute Inc |
Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau
|
JP7407461B2
(ja)
|
2018-12-19 |
2024-01-04 |
シャイ・セラピューティクス・エルエルシー |
がん、炎症性疾患、ras病、及び線維性疾患の処置のためのrasスーパーファミリーと相互作用する化合物
|
WO2020132700A1
(en)
|
2018-12-21 |
2020-06-25 |
Fgh Biotech Inc. |
Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
|
EP3897638A1
(de)
|
2018-12-21 |
2021-10-27 |
Kura Oncology, Inc. |
Therapien für plattenepithelkarzinome
|
EP3921038A1
(de)
|
2019-02-06 |
2021-12-15 |
Dice Alpha, Inc. |
Il-17a modulators and uses thereof
|
US20220142983A1
(en)
|
2019-03-01 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2020181165A1
(en)
|
2019-03-07 |
2020-09-10 |
Conatus Pharmaceuticals Inc. |
Caspase inhibitors and methods of use thereof
|
US20220143006A1
(en)
|
2019-03-15 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
AU2020254492A1
(en)
|
2019-03-29 |
2021-11-11 |
Kura Oncology, Inc. |
Methods of treating Squamous Cell Carcinomas with farnesyltransferase inhibitors
|
US20220168296A1
(en)
|
2019-04-01 |
2022-06-02 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2020223583A1
(en)
|
2019-05-02 |
2020-11-05 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
AU2020311404A1
(en)
|
2019-07-11 |
2022-03-03 |
Cura Therapeutics, Llc |
Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
|
AU2020310190A1
(en)
|
2019-07-11 |
2022-02-24 |
Cura Therapeutics, Llc |
Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
MX2022000570A
(es)
|
2019-07-26 |
2022-03-11 |
Espervita Therapeutics Inc |
Acidos mono- y dicarboxilicos hidrocarbonados de cadena larga funcionalizados y su uso para la prevencion o el tratamiento de enfermedad.
|
US11788091B2
(en)
|
2019-08-21 |
2023-10-17 |
University Of Virginia Patent Foundation |
Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
AU2020348685A1
(en)
|
2019-09-16 |
2022-04-14 |
Dice Alpha, Inc. |
IL-17A modulators and uses thereof
|
EP4034236A1
(de)
|
2019-09-26 |
2022-08-03 |
Abionyx Pharma SA |
Verbindungen zur behandlung von lebererkrankungen
|
JP2022551583A
(ja)
|
2019-10-01 |
2022-12-12 |
モレキュラー スキン セラピューティクス,インコーポレイティド |
Klk5/7デュアル阻害剤としてのベンゾキサジノン化合物
|
WO2021242970A1
(en)
|
2020-05-29 |
2021-12-02 |
Boulder Bioscience Llc |
Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
|
US20230227466A1
(en)
|
2020-06-18 |
2023-07-20 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
AU2021326546A1
(en)
|
2020-08-14 |
2023-04-13 |
Siteone Therapeutics, Inc. |
Non-hydrated ketone inhibitors of NaV1.7 for the treatment of pain
|
WO2022165000A1
(en)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Methods for the treatment of fibrotic disease
|
WO2022164997A1
(en)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Methods for the treatment of fibrotic disease
|
WO2022189856A1
(en)
|
2021-03-08 |
2022-09-15 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
KR20230169979A
(ko)
|
2021-03-10 |
2023-12-18 |
다이스 몰레큘스 에스브이, 인크. |
알파 v 베타 6 및 알파 v 베타 1 인테그린 억제제 및 그의 용도
|
WO2022226166A1
(en)
|
2021-04-22 |
2022-10-27 |
Protego Biopharma, Inc. |
Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
|
WO2022251533A1
(en)
|
2021-05-27 |
2022-12-01 |
Protego Biopharma, Inc. |
Heteroaryl diamide ire1/xbp1s activators
|
CA3234276A1
(en)
|
2021-11-30 |
2023-06-08 |
Kura Oncology, Inc. |
Macrocyclic compounds having farnesyltransferase inhibitory activity
|
WO2023129577A1
(en)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
WO2023192817A1
(en)
|
2022-03-28 |
2023-10-05 |
Isosterix, Inc. |
Inhibitors of the myst family of lysine acetyl transferases
|
US20230348909A1
(en)
|
2022-03-30 |
2023-11-02 |
Biomarin Pharmaceutical Inc. |
Dystrophin exon skipping oligonucleotides
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
US20230331693A1
(en)
|
2022-04-14 |
2023-10-19 |
Bristol-Myers Squibb Company |
Gspt1 compounds and methods of use of the novel compounds
|
WO2023201348A1
(en)
|
2022-04-15 |
2023-10-19 |
Celgene Corporation |
Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
|
WO2023211990A1
(en)
|
2022-04-25 |
2023-11-02 |
Siteone Therapeutics, Inc. |
Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
|
WO2023215781A1
(en)
|
2022-05-05 |
2023-11-09 |
Biomarin Pharmaceutical Inc. |
Method of treating duchenne muscular dystrophy
|
WO2024054832A1
(en)
|
2022-09-09 |
2024-03-14 |
Innovo Therapeutics, Inc. |
CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS
|
WO2024073473A1
(en)
|
2022-09-30 |
2024-04-04 |
Boulder Bioscience Llc |
Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
|